OABIOmniAb
About OmniAb
OmniAb (NASDAQ:OABI) specializes in leveraging its proprietary technology to discover and develop innovative antibody-based therapeutics for a broad range of diseases. The company thrives on a dynamic platform that includes advanced genetic engineering, immunization, and screening technologies designed to address complex therapeutic challenges. OmniAb's operations revolve around partnerships and collaborations with biopharmaceutical entities, with a mission to expedite the journey from discovery to clinical stages. The company's projects span oncology, immunology, and infectious diseases among other areas, showcasing a versatile and potent approach to tackling severe health issues. Objectively, OmniAb aims to harness its cutting-edge technology to push the boundaries of antibody therapy, optimizing efficacy, safety, and accessibility for patients worldwide.
What is OABI known for?
Snapshot
Public US
Ownership
2012
Year founded
84
Employees
California, United States
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Products and/or services of OmniAb
- Antibody discovery platform leveraging transgenic animals for developing human therapeutic antibodies with diverse and optimized immune repertoire.
- Humanized rodent models designed to produce a broad diversity of high-affinity human antibodies, facilitating rapid discovery and development of therapeutic candidates.
- Modular OmniRat, OmniMouse, and OmniFlic platforms, offering diverse options for monoclonal antibody development against challenging targets in multiple therapeutic areas.
- OmniChicken platform, providing unique capabilities for generating antibodies with high specificity and affinity, suitable for a variety of therapeutic applications.
- OmniClic, a specialized platform for the generation of bispecific antibodies, enhancing therapeutic potential through targeted dual-action mechanisms.
- Integrated antibody discovery and optimization services, supporting partners from early-stage research through to pre-clinical development.
OmniAb executive team
- Mr. Matthew W. FoehrPresident, CEO & Director
- Mr. Kurt A. GustafsonExecutive VP of Finance & CFO
- Mr. Charles S. Berkman J.D.Chief Legal Officer & Secretary
- Ms. Cia McCaffreyVice President of People & Talent
- Dr. Bill Harriman Ph.D.Senior Vice President of Antibody Discovery
- Dr. Christel Iffland Ph.D.Senior Vice President of Antibody Technologies
- Dr. Yasmina Noubia Abdiche Ph.D.Senior Vice President of Exploratory Research
- Mr. Todd Pettingill C.F.A.Vice President of Business Development & Strategy